However, due to retrospective design limitations, we were unable to collect disease activity scores (such as DAS28) and the effects of immunosuppressive treatment on inflammation control, therefore cannot determine whether CRP-squamous cell lung cancer association can be improved through aggressive anti-inflammatory treatment [25]. The gene discussed is CRP; the disease is squamous cell lung carcinoma.